1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Aldose Reductase

Aldose Reductase

Aldose reductase is a small, cytosolic, monomeric enzyme which belongs to the aldo-keto reductase superfamily. Aldose reductase catalyzes the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH)-dependent reduction of a wide variety of aromatic and aliphatic carbonyl compounds. It is implicated in the development of diabetic and galactosemic complications involving the lens, retina, nerves, and kidney.

Aldose reductase is both the key enzyme of the polyol pathway, whose activation under hyperglycemic conditions leads to the development of chronic diabetic complications, and the crucial promoter of inflammatory and cytotoxic conditions, even under a normoglycemic status. Aldose reductase represents an excellent drug target and a huge effort is being done to disclose novel compounds able to inhibit it.

Aldose Reductase Related Products (17):

Cat. No. Product Name Effect Purity
  • HY-N0102
    Isoliquiritigenin Inhibitor 98.17%
    Isoliquiritigenin is an anti-tumor flavonoid from the root of Glycyrrhiza glabra, which inhibits aldose reductase with an IC50 of 320 nM. Isoliquiritigenin is a potent inhibitor of influenza virus replication with an EC50 of 24.7 μM.
  • HY-66009
    Epalrestat Inhibitor 99.59%
    Epalrestat is an aldose reductase inhibitor for the treatment of diabetic neuropathy.
  • HY-105185
    Fidarestat Inhibitor 99.10%
    Fidarestat (SNK 860) is an inhibitor of aldose reductase, with IC50s of 26 nM, 33 μM, and 1.8 μM for aldose reductase, AKR1B10 and V301L AKR1B10, respectively; Fidarestat (SNK 860) has the potential to treat diabetic disease.
  • HY-15314
    Ranirestat Inhibitor 98.32%
    Ranirestat (AS-3201) potent and orally active aldose reductase (AR) inhibitor with IC50s of 11 nM and 15 nM for rat lens AR and recombinant human AR, respectively, and a Ki of 0.38 nM for recombinant human AR. Ranirestat has the potential for diabetic sensorimotor polyneuropathy treatment. Ranirestat also has a neuroprotective effect on diabetic retinas.
  • HY-106697
    Ponalrestat Inhibitor 98.07%
    Ponalrestat (ICI 128436) is an orally active, selective and noncompetitive aldose reductase (AKR1B1; ALR) inhibitor. Ponalrestat selectively inhibits ALR2 (Ki=7.7 nM) over ALR1 (Ki=60 μM). Ponalrestat inhibits the conversion of glucose to sorbitol.
  • HY-16500
    Tolrestat Inhibitor 98.85%
    Tolrestat is a potent, orally active aldose reductase inhibitor with IC50 of 35 nM.
  • HY-106198
    Lidorestat Inhibitor 99.50%
    Lidorestat (IDD-676) is a potent, selective and orally active aldose reductase inhibitor with an IC50 of 5 nM. Lidorestat can be used for chronic diabetes complications. Lidorestat also improves nerve conduction and reduces cataract formation.
  • HY-18967
    Aldose reductase-IN-1 Inhibitor 99.86%
    Aldose reductase-IN-1 is a inhibitor of aldose reductase with IC50 of 28.9 pM.
  • HY-129586
    AT-007 Inhibitor 99.33%
    AT-007 is an orally active central nervous system (CNS) penetrant Aldose Reductase inhibitor for treatment of Galactosemia with an IC50 value of 100 pM. AT-007 reduces toxic galactitol levels and prevents disease complications in GALT deficiency rats.
  • HY-B1202
    Alrestatin Inhibitor 99.80%
    Alrestatin is an inhibitor of aldose reductase, an enzyme involved in the pathogenesis of complications of diabetes mellitus, including diabetic neuropathy.
  • HY-16255
    Imirestat Inhibitor 99.09%
    Imirestat (AL 1576) is an aldose reductase inhibitor, used for the treatment of diabetes.
  • HY-N0033
    Poliumoside Inhibitor
    Poliumoside, a caffeoylated phenylpropanoid glycoside, is isolated from Brandisia hancei stems and leaves. Poliumoside is an advanced glycation end product (AGE) formation and rat lens aldose reductase (RLAR) inhibitor, with IC50s of 19.69 and 8.47 μM, respectively. Poliumoside also has antiinflammatory and antioxidant activity.
  • HY-50289
    Sorbinil Inhibitor ≥98.0%
    Sorbinil, is an Aldose reductase inhibitor (ARI). Sorbinil plays therapeutic role in treating diabetes and diabetic complications, decreases AR activity and inhibits polyol pathway, it to be found comparatively safer than other ARIs for human use.
  • HY-N4089
    Quercetin 3-gentiobioside Inhibitor
    Quercetin 3-gentiobioside is isolated from A. iwayomogi, AR and AGE formation inhibitor, demonstrates biological activities against Aldose reductase (AR) and the formation of advanced glycation endproducts (AGEs).
  • HY-N6883
    6-Methoxytricin Inhibitor
    6-Methoxytricin (Compound 6) is an flavonoid isolated from Artemisia iwayomogi. 6-Methoxytricin (Compound 6) is an inhibitor on aldose reductase (AR) and advanced glycation endproduct (AGE) formation activities with IC50 values of 30.29 μM and 134.88 μM, respectively. 6-Methoxytricin (Compound 6) has potential as an anti-diabetic complications agent.
  • HY-B1202A
    Alrestatin sodium Inhibitor
    Alrestatin sodium is an inhibitor of aldose reductase, an enzyme involved in the pathogenesis of complications of diabetes mellitus, including diabetic neuropathy.
  • HY-16433
    Risarestat Inhibitor 98.09%
    Risarestat (CT-112), an aldose reductase inhibitor, is developed for the treatment of diabetic complications.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.